Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies.
Bennett H, Gordon J, Jones B, Ward T, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Bennett H, et al. Eur J Health Econ. 2017 Nov;18(8):1001-1011. doi: 10.1007/s10198-016-0844-8. Epub 2016 Nov 1. Eur J Health Econ. 2017. PMID: 27803989
This study aimed to quantify how reduced HCV transmission changes the cost-effectiveness of new direct-acting antiviral (DAA) regimens as a function of treatment uptake rates. ...Dependent on patient genotype, the …
This study aimed to quantify how reduced HCV transmission changes the cost-effectiveness of new direct- …
Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
Kwon JA, Chambers GM, Luciani F, Zhang L, Kinathil S, Kim D, Thein HH, Botha W, Thompson S, Lloyd A, Yap L, Gray RT, Butler T. Kwon JA, et al. PLoS One. 2021 Feb 11;16(2):e0245896. doi: 10.1371/journal.pone.0245896. eCollection 2021. PLoS One. 2021. PMID: 33571196 Free PMC article.
In Australian prisons approximately 20% of inmates are chronically infected with hepatitis C virus (HCV), providing an important population for targeted treatment and prevention. A dynamic mathematical model of HCV transmission was used to assess the …
In Australian prisons approximately 20% of inmates are chronically infected with hepatitis C virus (HCV), providing an importa …